

Organized by:



In collaboration with:



Under the auspices of:



IMMUNOTHERAPY bridge 2022

Naples, Italy
November 30th - December 1st, 2022
Royal Continental Hotel

2022

GENERAL INFORMATION



CME PROVIDER AND ORGANIZING SECRETARIAT:

3P Solution Srl

Corso Magenta 81, 20123 Milan

Phone +39 02 36631574

www.3psolution.it

info@3psolution.it

info@melanomabridge.org

OFFICIAL LANGUAGE:

The official language is English

REGISTRATION:

Only registered attendees will be admitted to the meeting.

The registration fee includes:

- participation in the scientific sessions
- congress bags (badge, notepad, pen)
- coffee breaks and lunches from Nov 30th to Dec 1st

GENERAL INFORMATION

CONGRESS VENUE:


Royal Continental Hotel

Via Partenope, 38/44

80121 - Naples

+39 081 245 2068

<http://www.royalgroup.it/royalcontinental/it>



AIRPORT

RAILWAY STATION

CONGRESS
VENUE

SCIENTIFIC RATIONAL

Over the last few years, an extensive research has improved our understanding of tumor immunology and enabled the development of novel treatments that can harness the patient's immune system and prevent immune escape.

Through numerous clinical trials and real-world experience, a large amount of evidence of the potential for long-term survival with immunotherapy agents has been accumulated in various types of malignancy, starting from melanoma to extend to other tumors.

The results of these studies have also highlighted a number of recurring observations with immuno-oncology agents, including their potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The clinical success of immune checkpoint blockade with anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and anti-programmed death (PD)-1/PD-ligand (L)1 inhibitor in melanoma and other cancers has encouraged increasing development of other immunotherapies, particularly monoclonal antibodies with other immune targets, adoptive cell transfer and vaccines. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Study results have highlighted a number of recurring observations, including the immunotherapy potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The successes of the immune-oncology is strongly correlated with the immune system ability of "memory" and adaptability, to improve the time of survival and without selecting resistant form of tumoral cells. Another advantage is that the efficacy of immunotherapy drugs does not seem to be particularly influenced by histology and mutations.

First session of the congress will be jointly organized with the Society for ImmunoTherapy of Cancer (SITC).

Hence, the state of the art of immunotherapy from the clinical point of view in various types of malignancies will be exhaustively discussed (lung, head and neck, ovarian, breast, gastrointestinal tract and lymphomas) and on targeting cancer through stimulation of innate immunity with intratumorals.

Then the "Great Debate" sessions, where counterpoint views from leading experts on specific controversial clinical issues will be presented and discussed from different points of view.

Conclusions will be drawn after the last session on Neo-Adjuvant therapies in different types of cancer.

SCIENTIFIC PROGRAM

Wednesday, Nov 30th, 2022 | AUDITORIUM



10:00 am *Registration***

10:40 am Introduction and objectives
Paolo A. Ascierto

**SITC SESSION
CELL THERAPIES**

Chairpersons: Lisa H. Butterfield, Marcela V. Maus

10:45 am TCR-T, TILs and CAR-T
Daniel J. Powell

11:00 am Engineered NK cells for cancer immunotherapy
Katy Rezvani

11:15 am Biological drivers of CAR T cell failure
Nathan Singh

11:30 am Biomarkers and immune cell subsets
Anne Monette

11:45 am Best of SITC 2022 for clinical development and trials
Paolo A. Ascierto

12:00 pm Discussion

12:30 pm **LECTURE - Breast Cancer**
Michelino De Laurentiis

01:00 pm *Lunch***

02:00 pm **SYMPOSIUM – What's new in Immunotherapy**

Chairperson: Paolo A. Ascierto

Renal Cell Carcinoma, **Camillo Porta**

Lung & Mesothelioma, **Alessandro Morabito**

New Immunotherapy options in Upper GI Cancer, **Sara Lonardi**

Discussion

SCIENTIFIC PROGRAM

Wednesday, Nov 30th, 2022



SESSION 2

TRENDS IN IMMUNOTHERAPY

Chairpersons: **Bruno Daniele, Bernard A. Fox**

02:50 pm Interrogating microenvironment responses to neoadjuvant cancer immunotherapy
Robert L. Ferris

03:05 pm Immunotherapy data in GU Cancers: what's new and what's confirmed
Sergio Bracarda

03:20 pm Colorectal Cancer
Antonio Avallone

03:35 pm Translating novel immunotherapy combinations in GI Cancer
Gregory B. Lesinski

03:50 pm Breast cancer immunotherapy: moving forward
Leisha A. Emens

04:05 pm Progress in Immunotherapy for Ovarian Cancer
Kunle Odunsi

04:20 pm Trends in lymphoma immunotherapy and lessons for solid tumors
Joshua Brody

04:35 pm Discussion

05:05 pm *Coffee break***

GREAT DEBATE SESSION

Chairpersons: **Paolo A. Ascierto, Bernard A. Fox, Igor Puzanov**

05:20 pm Can computational biology approach improve clinical trial design? Yes or no
Samir N. Khleif, Robert A. Beckman

05:50 pm Discussion

06:00 pm Cell therapy for solid tumors: yes or no?
Renier Brentjens, Kunle Odunsi

06:30 pm Discussion

SCIENTIFIC PROGRAM

Thursday, Dec 1st, 2022



SESSION 3

DRIVERS OF IMMUNE RESPONSES

Chairpersons: Alfredo Budillon, Luigi Buonaguro

- 09:30 am Immunogenicity and therapeutic cross-protection to NRAS Q61 public neoantigens
Christopher A. Klebanoff
- 09:45 am Intracranial administration of immune checkpoint blockade in patients with recurrent glioblastoma
Bart Neyns
- 10:00 am Bispecific antibodies in cancer immunotherapy
Omid Hamid
- 10:15 am Harnessing novel CD4 T cell-based therapies against solid tumors
Chrystal M. Paulos
- 10:30 am Therapeutic strategies to activate innate immunity in prostate cancer
Akash Patnaik
- 10:45 am Targeting neutrophils to enhance antitumor immunity
Brahm Segal
- 11:00 am *Coffee break***
- 11:15 am New clinical data with novel immune checkpoints
Tomas Kirchhoff
- 11:30 am Mechanisms of ICI toxicities across tumor types
Ryan J. Sullivan
- 11:45 am Long-term toxicity and the impact on quality of life
Douglas B. Johnson
- 12:00 pm Evidence for adapting radiotherapy to immune checkpoint blockade
Silvia Chiara Formenti
- 12:15 pm Enhancing clinical genomics datasets with multimodal EHR data and imaging
Carlo Bifulco
- 12:30 pm Discussion
- 12:45 pm **SYMPOSIUM - Non Melanoma Skin Cancer**
Update in the treatment of Non-Melanoma Skin Cancers, BCC and CSCC
Paolo A. Ascierto, Dirk Schadendorf
- 01:35 pm *Lunch***

SCIENTIFIC PROGRAM

Thursday, Dec 1st, 2022



GREAT DEBATE SESSION

Chairpersons: **Paolo A. Ascierto, Bernard A. Fox, Igor Puzanov**

02:35 pm Periphery/blood biomarkers VS TME biomarkers
Ryan J. Sullivan, Samir N. Khleif

03:05 pm Discussion

03:15 pm CAR-T vs CAR-T NK
Marco Ruella, Katy Rezvani

03:45 pm Discussion

SESSION

NEOADJUVANT IMMUNOTHERAPY

Chairpersons: **Paolo A. Ascierto, Elizabeth M. Burton**

03:55 pm NSCLC
Tina Cascone

04:10 pm Immunotherapy for High-Risk Early TNBC
Leisha A. Emens

04:25 pm Non melanoma skin cancer
Neil D. Gross

04:40 pm Pan-Tumor application of immune-related Pathologic Response Criteria (irPRC)
Tricia Cottrell

04:55 pm Colon Cancer
Myriam Chalabi

05:10 pm Personalization of neoadjuvant immunotherapy in melanoma
Christian Blank

05:25 pm Discussion

05:55 pm Conclusions
Paolo A. Ascierto, Bernard A. Fox, Igor Puzanov

PRESIDENCY



Paolo A. Ascierto

Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute, IRCCS "Fondazione G. Pascale", Naples, Italy



Bernard A. Fox

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US



Patrick Hwu

President & CEO, Moffitt Cancer Center, Tampa, FL, US



Igor Puzanov

Senior Vice President, Clinical Investigation; Professor of Oncology and Medicine, Director of Center for Early Phase Clinical Trials Division, Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

SCIENTIFIC BOARD

Sanjiv S. Agarwala

Professor of Hematology & Oncology, Temple University School of Medicine, Philadelphia, PA, US

Paolo A. Ascierto

Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute, IRCCS "Fondazione G. Pascale", Naples, Italy

Carlo Bifulco

Medical Director of Oncological Molecular Pathology and Pathology Informatics, Providence Oregon Regional Laboratory; Director, Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Elizabeth M. Burton

Director, Research Planning & Development, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, US

Lisa H. Butterfield

Adjunct Professor, Microbiology and Immunology, University of California San Francisco; Vice President, PICI Research Center/ PICI Research & Development, San Francisco, CA, US

Corrado Caracò

Melanoma and Skin Tumor Surgery, National Cancer Institute, IRCCS "Fondazione G. Pascale", Naples, Italy

Mary Dean

Executive Director, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

SCIENTIFIC BOARD

Sandra Demaria

Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology, Weill Cornell Medical College, New York, NY, US

Reinhard Dummer

Vice Director, Department of Dermatology; Director, Clinical Trials Comprehensive Cancer Center Zurich (CCCZ), University Hospital Zurich, Zurich, Switzerland

Bernard A. Fox

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Jerome Galon

Research Director, National Institute of Health and Medical Research (INSERM), Director, Integrative Cancer Immunology Team, Cordeliers Research Center, Paris, France

Claus Garbe

Professor of Dermatology, President of the European Association of DermatoOncology (EADO), Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany

Omid Hamid

Chief of Research/ Immuno-Oncology, Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, US

Patrick Hwu

President & CEO, Moffitt Cancer Center, Tampa, FL, US

Giuseppe Masucci

Associate Professor, Department of Oncology-Pathology and KcRN, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

Olivier Michielin

Full Professor, Chair of Precision Oncology Center, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland

Iman Osman

Rudolf L. Baer MD Professor of Dermatology, Professor, Departments of Medicine (Oncology) and Urology, Director, Interdisciplinary Melanoma Program, Associate Dean for Translational Research Support, NYU Grossman School of Medicine, New York, NY, US

Giuseppe Palmieri

Full Professor of Medical Oncology, University of Sassari; Immuno-Oncology & Targeted Cancer Biotherapies, Sassari University Hospital; Associate Researcher, Head of Unit of Cancer Genetics, National Research Council (CNR); Head, Institute of Genetic & Biomedical Research (IRGB), Sassari, Italy

Michael A. Postow

Chief, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, US

Igor Puzanov

Senior Vice President, Clinical Investigation; Professor of Oncology and Medicine, Director of Center for Early Phase Clinical Trials Division, Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

Magdalena Thurin

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, US

Tara Withington

Executive Director Emeritus, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

FACULTY

Paolo A. Ascierto

Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute, IRCCS "Fondazione G. Pascale", Naples, Italy

Antonio Avallone

Unit of Abdominal Medical Oncology, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

Robert A. Beckman

Professor of Oncology and Biostatistics, Bioinformatics, and Biomathematics, Lombardi Comprehensive Cancer Center, Innovation Center of Biomedical Informatics, Georgetown University Medical Center, Washington, DC, US

Carlo Bifulco

Medical Director of Oncological Molecular Pathology and Pathology Informatics, Providence Oregon Regional Laboratory, Director of Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Christian Blank

Medical Oncology and Research Group Leader Tumor Immunology, Netherlands Cancer Institute, Amsterdam; Medical Oncology, Leiden University Medical Center (LUMC), Leiden, Netherlands

Sergio Bracarda

Director, Department of Oncology and Medical & Translational Oncology Unit, Santa Maria Hospital, Terni, Italy

Renier Brentjens

Deputy Director & Chair, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

Joshua Brody

Director, Lymphoma Immunotherapy Program, Hess Center for Science and Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, US

Alfredo Budillon

Scientific Director, National Cancer Institute, IRCCS Fondazione "G. Pascale", Naples, Italy

Luigi Buonaguro

Director Innovative Immunological Models Unit, National Cancer Institute, IRCCS Fondazione "G. Pascale", Naples, Italy

Elizabeth M. Burton

Director, Research Planning & Development, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US

Lisa H. Butterfield

Adjunct Professor, Microbiology and Immunology, University of California San Francisco; Vice President, PICI Research Center/ PICI Research & Development, San Francisco, CA, US

Tina Cascone

Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, US

Myriam Chalabi

Medical Oncologist, GI cancers, Netherlands Cancer Institute, Amsterdam, Netherlands

Tricia Cottrell

Assistant Professor, Queen's Cancer Research Institute, Kingston, Ontario, Canada

Bruno Daniele

Director, Oncology Unit, "Ospedale del Mare" Hospital, Naples, Italy

Michelino De Laurentiis

Director of SC Experimental Oncology Clinic of Senology; Director of the Corp-S Department for Research of Oncology Pathways of the Toracic District, IRCCS Fondazione "G. Pascale", Naples, Italy

FACULTY

Leisha A. Emens

Professor of Medicine, Director of Translational Immunotherapy for the Women's Cancer Research Center, Co-Leader, Hillman Cancer Immunology/Immunotherapy Program, UPMC Hillman Cancer Center/Magee Women's Hospital, Pittsburgh, PA, US

Robert L. Ferris

Director, UPMC Hillman Cancer Center, Professor of Oncology, Associate Vice Chancellor for Cancer Research Center, Professor of Otolaryngology, of Immunology, and of Radiation Oncology, University Pittsburgh School of Medicine, PA, US

Silvia Chiara Formenti

Chairman of the Department of Radiation Oncology, Weill Cornell Medicine; Associate Director of the Meyer Cancer Center, Radiation Oncologist in Chief, New York-Presbyterian Hospital, New York, NY, US

Bernard A. Fox

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Childs Research Institute, Providence Cancer Institute, Portland, OR, US

Neil D. Gross

Professor and Director of Clinical Research, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, US

Omid Hamid

Chief of Research/Immuno-Oncology, Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, US

Douglas B. Johnson

Associate Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, US

Samir N. Khleif

Director of the Center for Immunology and Immunotherapy, Director of The Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, US

Tomas Kirchhoff

Associate Professor, Department of Population Health, Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY, US

Christopher A. Klebanoff

Memorial Sloan Kettering Cancer Center, New York, NY; The Parker Institute for Cancer Immunotherapy, San Francisco, CA, US

Gregory B. Lesinski

Professor, Vice Chair for Basic Research, Department of Hematology & Medical Oncology, Associate Director for Basic Research, Co-Director, Translational GI Malignancy Program, Winship Cancer Institute of Emory University, Atlanta, GA, US

Sara Lonardi

Chief of Gastrointestinal Cancers Unit, Veneto Institute of Oncology - IRCCS, Padova, Italy

Marcela V. Maus

Associate Professor of Medicine, Harvard Medical School; Director of Cellular Immunotherapy, Cancer Center, Massachusetts General Hospital, Boston, MA, US

Anne Monette

Senior Research Associate, Lady Davis Institute for Medical Research; Sir Mortimer B. Davis - Jewish General Hospital, Montreal, Quebec, Canada

FACULTY

Alessandro Morabito

Director of Thoracic Medical Oncology, National Cancer Institute, IRRCS "Fondazione G. Pascale", Naples, Italy

Bart Neyns

Head of Department Medical Oncology, Universitair Ziekenhuis (UZ) Brussel; Clinical Professor at the Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), Brussels, Belgium

Kunle Odunsi

Director, University of Chicago Medicine Comprehensive Cancer Center; Dean for Oncology, Biological Sciences Division, The University of Chicago, Chicago, IL, US

Akash Patnaik

Director, Laboratory for Prostate Cancer Developmental Therapeutics/ImmunoOncology Attending Physician, Genitourinary Oncology Program University of Chicago Comprehensive Cancer Center Chicago, IL, US

Chrystal M. Paulos

Associate Professor, Department of Surgery / Microbiology & Immunology, Director of Translational Research, Cutaneous Malignancies, Winship Cancer Institute at Emory University Atlanta, GA, US

Camillo Porta

Department of Biomedical Sciences and Human Oncology, University of Bari "A. Moro"; Chief, Division of Medical Oncology, AOU Policlinico Consorziale, Bari, Italy

Daniel J. Powell

Associate Professor of Pathology & Laboratory Medicine; Scientific Director of Immunotherapy in the Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia, PA, US

Igor Puzanov

Senior Vice President, Clinical Investigation; Professor of Oncology and Medicine, Director of Center for Early Phase Clinical Trials Division, Chief, Melanoma Section, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

Katy Rezvani

Sally Cooper Murray Chair in Cancer Research, Professor of Medicine, Chief, Section of Cellular Therapy, Director, Cell Engineering GMP Lab, Executive Director, Adoptive Cell therapy Platform, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, US

Marco Ruella

Assistant Professor of Medicine, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, US

Dirk Schadendorf

Director, Clinic for Dermatology, University Hospital Essen, Essen, Germany

Brahm Segal

Chair, Department of Internal Medicine, Chief, Division of Infectious Diseases, Professor of Oncology, Member, Department of Immunology, Roswell Park Comprehensive Cancer Center; Professor of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, US

Nathan Singh

Assistant Professor, Department of Medicine, Oncology Division, Stem Cell Biology, Washington University in St. Louis, St. Louis, MO, US

Ryan J. Sullivan

Associate Professor of Medicine, Harvard Medical School; Associate Professor of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, US

CONTINUING MEDICAL EDUCATION

3P Solution has been accredited by the Ministry of Health as a CME Standard Provider (code 327, authorized on October 15th, 2012).

3P Solution owns the responsibility for the content, quality and ethical correctness of this CME activity.

Immunotherapy Bridge Congress has been accredited (ID CME 327-365182) with 4,2 CME credits with a formative technical-professional objective "Technical professional content (knowledge and competences) specifications of each profession, of all specialization and ultraspecialist activity. Rare disease and Gender medicine", belonging to formative technical professional objective area, for 201 participants of the following professions: medical doctors, pharmacists, biologists, nurses, pediatric nurse.

The number of attendees can not exceed the number of accredited participants. If the number of participants is exceeded, attendees will be admitted to the scientific sessions on the basis of registration order.

In order to receive credits, participants must:

1. Attend at least 90% of the accredited CME sessions (attendance check: required sign at the beginning and at the end of works each day);
2. Complete the evaluation form at the end of the Congress.

CME certificate will be sent at the end of the validation procedure.

MY ECM

Age.na.s activated MyEcm service (personalized page available to any health professional), which enables you to:

1. Consult the CME events offer;
2. Refer to the summary of events attended and earned credits;
3. Provide an assessment of courses organized by the Provider.

To access online services please log on to <http://ape.agenas.it/professionisti/myecm>.

If this meeting fulfilled your expectations, please click on  and give your assessment.

IT IS HIGHLY RECOMMENDED TO WEAR A FFP2 MASK TO ATTEND THE CONGRESS

Immunotherapy Bridge is sponsored by an unrestricted grant from:

PLATINUM SPONSOR

SANOFI GENZYME  | **REGENERON**

GOLD SPONSOR

 Bristol Myers Squibb™

SILVER SPONSOR

 **MSD**

SPONSOR

MERCK 

 Roche


SUN
PHARMA